---
title: "002382.SZ (002382.SZ) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/002382.SZ/news.md"
symbol: "002382.SZ"
name: "002382.SZ"
parent: "https://longbridge.com/zh-CN/quote/002382.SZ.md"
datetime: "2026-03-12T06:59:30.957Z"
locales:
  - [en](https://longbridge.com/en/quote/002382.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002382.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002382.SZ/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/002382.SZ/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/002382.SZ/news.md)


# 002382.SZ (002382.SZ) — 相关新闻

### [](https://longbridge.com/zh-CN/news/278647506.md)
*2026-03-11T02:53:18.000Z*
> The A-share medical device sector fluctuated upward, with ANDON HEALTH and BIOLIGHT hitting the daily limit, while ZHEND

### [BLUE SAIL MEDICAL IVL Shockwave Balloon System Launches in Overseas Market](https://longbridge.com/zh-CN/news/278509933.md)
*2026-03-10T07:36:42.000Z*
> BLUE SAIL MEDICAL's IVL shockwave balloon system has successfully entered the international market, with the first batch

### [BLUE SAIL MEDICAL: Expects glove business to shift from significant losses in 2025 to clear profitability in 2026](https://longbridge.com/zh-CN/news/278470007.md)
*2026-03-10T01:21:11.000Z*
> BLUE SAIL MEDICAL (002382) expects its glove business to achieve significant profitability by 2026, ending the substanti

### [Yide partners with global pharmaceutical companies to enter the U.S. inhaler market, and the rise in Taiwan stocks indicates the coexistence of technology and medical opportunities](https://longbridge.com/zh-CN/news/274801380.md)
*2026-02-04T11:15:04.000Z*
> Yide is collaborating with global pharmaceutical companies to enter the U.S. inhaler market, enhancing international vis

### [BLUE SAIL MEDICAL expects a loss of 650 million to 850 million in 2025, and also needs to pay back taxes exceeding 169 million yuan](https://longbridge.com/zh-CN/news/274619574.md)
*2026-02-03T07:59:54.000Z*
> BLUE SAIL MEDICAL expects a net loss of 650 million to 850 million yuan in 2025, with the loss margin further widening c

### [BLUE SAIL MEDICAL's cardiovascular business turns a profit, innovative products accelerate volume growth](https://longbridge.com/zh-CN/news/274311137.md)
*2026-01-30T12:37:13.000Z*
> BLUE SAIL MEDICAL announced in its 2025 annual performance forecast that the cardiovascular and cerebrovascular division

### [BLUE SAIL MEDICAL released its performance forecast for 2025, with losses expected to be released and recovery in sight](https://longbridge.com/zh-CN/news/274297378.md)
*2026-01-30T11:10:14.000Z*
> On the evening of January 30th, BLUE SAIL MEDICAL released its annual performance forecast for 2025, expecting a loss of

### [BLUE SAIL MEDICAL's performance forecast is revealed, pay attention to whether it can "squat and jump" after the concentrated release of pressure](https://longbridge.com/zh-CN/news/274295167.md)
*2026-01-30T10:54:10.000Z*
> BLUE SAIL MEDICAL expects a loss of 650 million to 850 million yuan in 2025, an increase compared to the losses in the f

### [Shenwan Hongyuan: Leading companies have successfully won bids in the centralized procurement as scheduled, maintaining a positive outlook on the long-term growth potential of high-value consumables](https://longbridge.com/zh-CN/news/273024609.md)
*2026-01-20T03:19:02.000Z*
> Shenwan Hongyuan released a research report stating that the selection results of the sixth batch of national organized 

### [35.7 million yuan acquired 51% equity of Hunan Lanyi! eDiagnosis has made two acquisitions within a month, can it open a second growth curve?](https://longbridge.com/zh-CN/news/272990300.md)
*2026-01-19T16:13:08.000Z*
> eDiagnosis acquired 51% equity of Hunan Lanyi for 35.701 million yuan, becoming its controlling subsidiary, marking its